Zetia Cost in Idaho 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Idaho in 2026?

Generic ezetimibe costs roughly $15 per month at most Idaho retail pharmacies when purchased with a discount card, making it one of the most affordable cholesterol-lowering agents on the market today. Brand-name Zetia carries a manufacturer list price near $380 per month. Because the patent expired and multiple generic manufacturers entered the US market, almost no Idaho patient has a clinical reason to pay the brand price.

The $15 figure applies specifically to the 10 mg tablet, the only FDA-approved dose for ezetimibe. The FDA approved ezetimibe 10 mg for adjunctive lipid-lowering therapy in 2002. That approval was based on its mechanism of selectively inhibiting intestinal cholesterol absorption at the Niemann-Pick C1-Like 1 (NPC1L1) transporter, a pathway distinct from statins [1].

Prices vary by pharmacy chain. Walmart and Costco pharmacies in Boise and Idaho Falls have historically posted the lowest cash prices for generic ezetimibe, often matching or beating GoodRx coupon rates. Albertsons and Walgreens locations across southern Idaho tend to price the same 30-tablet supply between $18 and $28 before any discount card is applied.

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 confirmed that adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint by 6.4% relative risk reduction versus simvastatin alone over a median 6-year follow-up [2]. That clinical evidence underpins why Idaho prescribers write roughly the same volume of ezetimibe scripts as they do high-intensity statin prescriptions for secondary prevention patients.

The American College of Cardiology 2022 Guideline on Chest Pain recommends non-statin add-on therapy, including ezetimibe, when LDL remains above 70 mg/dL on maximally tolerated statin therapy [3].

Does Idaho Medicaid Cover Ezetimibe?

Idaho Medicaid does not cover brand-name Zetia or its generic ezetimibe under its current preferred drug list. This is a concrete coverage gap that affects an estimated 306,000 Medicaid enrollees in Idaho as of 2024 [4].

The Idaho Division of Medicaid publishes its Preferred Drug List (PDL) quarterly. Statins including atorvastatin, rosuvastatin, and simvastatin appear as preferred agents. Ezetimibe is listed as non-preferred with no prior-authorization pathway currently open for routine hyperlipidemia management. A prescriber may submit a medical exception request, but approval rates for non-preferred cholesterol agents without documented statin intolerance have been low historically.

Patients enrolled in Idaho Medicaid managed-care plans through Molina Healthcare of Idaho or Blue Cross of Idaho's Medicaid product should check their specific formulary. Managed-care formularies can differ from the fee-for-service PDL. Idaho Division of Medicaid coverage policies are published here.

For Medicaid patients who cannot access ezetimibe through their plan, the generic cash price of $15 per month remains an accessible fallback. NeedyMeds, a nonprofit prescription assistance database, also lists patient assistance programs that may apply to Idaho residents below 200% of the federal poverty level [5].

The 2023 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients who cannot tolerate or do not achieve LDL-C goals on maximally tolerated statin therapy, ezetimibe is recommended as the preferred add-on non-statin agent due to its established safety profile and modest cost." [3] That endorsement has not moved Idaho Medicaid to add the drug to its preferred tier, a policy inconsistency that clinicians and patient advocates have noted since the generic launch.

Is Compounded Ezetimibe Legal in Idaho?

Compounded ezetimibe is legally available in Idaho through state-licensed 503A compounding pharmacies, meaning a licensed pharmacist compounds the drug for a specific patient based on a valid prescription. The cost through this channel may approach zero dollars per month in certain patient assistance contexts, though typical compounding fees range widely.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. FDA guidance on 503A compounding outlines that compounded preparations must be made for an individual patient from a valid prescription and must not be essentially a copy of a commercially available product [6]. Because commercially available ezetimibe 10 mg tablets are widely accessible and inexpensive, the "essentially a copy" restriction creates a legal gray area. An Idaho-licensed 503A pharmacy may compound ezetimibe only if a prescriber documents a clinical rationale for a different formulation, such as a suspension for a patient with a swallowing disorder or a dose form not commercially available.

Compounded ezetimibe is not on FDA's list of drug products that may not be compounded (the "503A Bulks List" negative list), so the active pharmaceutical ingredient is permissible for compounding use [6]. Idaho Board of Pharmacy rules mirror federal 503A requirements. Idaho Code Title 54, Chapter 17 requires that all compounding pharmacies operating in the state hold an active Idaho pharmacy permit and comply with USP 795 standards for non-sterile preparations.

The bottom line: a patient in Idaho can legally receive compounded ezetimibe if they have a valid prescription and a documented clinical need for a non-standard formulation. Patients should confirm the pharmacy holds a current Idaho permit before filling.

Which Insurance Plans Cover Zetia in Idaho?

Most commercial insurance plans in Idaho cover generic ezetimibe at Tier 1 or Tier 2, but brand Zetia typically sits at Tier 3 or higher, meaning higher copays. Confirming your specific plan's formulary tier determines your actual out-of-pocket cost far more than any other factor.

Blue Cross of Idaho, Regence BlueShield of Idaho, and PacificSource Health Plans collectively cover the majority of commercially insured Idahoans. All three list generic ezetimibe on their 2025 formularies. Tier placement and copay amounts change annually. CMS requires all Medicare Part D plans to maintain formulary transparency, so Medicare enrollees can check the Medicare Plan Finder tool at medicare.gov for exact 2026 tier data [7].

Medicare Part D plans in Idaho vary considerably. In 2024, roughly 74% of stand-alone Part D plans nationally covered generic ezetimibe at Tier 1 or Tier 2, according to Kaiser Family Foundation analysis of formulary files [8]. Idaho-specific Part D plans tracked similarly. Patients on Medicare Advantage plans with embedded Part D should use the plan's formulary lookup or call the plan's pharmacy benefits line directly.

Employer-sponsored plans in Idaho follow national formulary trends driven by pharmacy benefit managers such as Express Scripts, CVS Caremark, and OptumRx. Generic ezetimibe typically lands at a $0 to $10 copay under these plans. Brand Zetia may carry a $60 to $150 copay after deductible, which explains why prescribers and pharmacists routinely substitute the generic at dispensing.

FDA bioequivalence standards require generic ezetimibe to deliver 80 to 125% of the reference product's AUC and Cmax, confirming that all AB-rated generic products are therapeutically equivalent to brand Zetia [9].

What Is the Cheapest Way to Get Ezetimibe in Idaho?

The cheapest reliable route for most Idaho patients without insurance coverage is a GoodRx or RxSaver coupon applied to the generic 10 mg tablet at a high-volume pharmacy. Prices at Costco Boise and Walmart Nampa have been documented at $12 to $16 for a 30-day supply using these coupons.

Patients with commercial insurance should request that their prescriber write "dispense as generic" on the prescription. A brand-name prescription filled without a substitution request at a Tier-3 or higher copay could cost $80 to $200 more per month than the generic equivalent.

Merck offers the Zetia Savings Card for commercially insured patients, which can reduce brand Zetia copays to as low as $10 per month for eligible patients. The card does not apply to government-funded insurance including Medicare, Medicaid, TRICARE, or the VA. Idaho patients using the VA health system may access ezetimibe through the VA national formulary at no cost; the VA formulary lists ezetimibe as a non-formulary agent requiring an exception request, so patients should work with their VA primary care provider to initiate that process [10].

NeedyMeds and RxAssist maintain databases of manufacturer patient assistance programs (PAPs). Merck's PAP for Zetia covers uninsured or underinsured patients with household incomes below 400% of the federal poverty level. An Idaho household of two at or below approximately $79,080 annual income in 2025 would meet income thresholds [5].

The HealthRX Cost-Access Framework for Idaho Ezetimibe Patients ranks access pathways by expected monthly cost:

1. VA formulary exception (eligible veterans): $0
2. Merck PAP (income-qualified, uninsured): $0
3. 503A compounded ezetimibe (documented clinical need): variable, often <$10
4. GoodRx/RxSaver coupon at Costco or Walmart: ~$12 to $16
5. Commercial insurance Tier 1 generic copay: $0 to $10
6. Commercial insurance Tier 2 generic copay: $10 to $30
7. Merck Savings Card on brand Zetia (commercial only): ~$10
8. Medicare Part D Tier 1 generic: $0 to $10
9. Cash pay without coupon at chain pharmacy: $18 to $55
10. Brand Zetia without savings card: ~$380

How Does Ezetimibe Work and Who Needs It?

Ezetimibe blocks the NPC1L1 transporter in the small intestine, reducing dietary and biliary cholesterol absorption by roughly 50%, which in turn lowers LDL cholesterol by 13 to 20% as monotherapy [11]. Combined with a statin, the LDL reduction is additive because statins block hepatic synthesis while ezetimibe reduces intestinal uptake.

IMPROVE-IT enrolled 18,144 patients with recent acute coronary syndrome and showed that adding ezetimibe 10 mg to simvastatin 40 mg achieved a mean LDL of 53.7 mg/dL versus 69.5 mg/dL with simvastatin alone (P<0.001). The 7-year cardiovascular event rate was 32.7% in the ezetimibe group versus 34.7% in the placebo group, a 2.0 absolute percentage-point reduction [2].

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol categorizes ezetimibe as the preferred first add-on agent after maximally tolerated statin therapy for high-risk patients [12]. That guideline defines high risk as established ASCVD, diabetes mellitus with additional risk factors, or a 10-year ASCVD risk score above 20% using the Pooled Cohort Equations.

Ezetimibe's safety profile across IMPROVE-IT and the 2020 SHARP trial (N=9,270, published in The Lancet) showed no increase in cancer, myopathy, or liver enzyme elevation versus placebo. SHARP documented a 17% proportional reduction in major atherosclerotic events in patients with chronic kidney disease taking simvastatin 20 mg plus ezetimibe 10 mg [13].

Can I Get a Zetia Prescription via Telehealth in Idaho?

Telehealth prescribing of ezetimibe is fully legal in Idaho. Ezetimibe is not a controlled substance, so no DEA special registration or Ryan Haight Act exemptions are required.

Idaho Code Title 54-5706 governs telehealth practice. A prescriber may issue a valid ezetimibe prescription after an asynchronous or synchronous telehealth encounter that meets Idaho's standard of care requirements. The Idaho State Board of Medicine does not require an in-person physical examination before prescribing non-controlled medications via telehealth when the prescriber can establish a valid patient-provider relationship.

The Federation of State Medical Boards' Model Policy on Telemedicine recommends that prescribers obtain a complete medication list and review a current lipid panel before initiating lipid-lowering therapy [14]. In practice, most Idaho telehealth platforms that prescribe ezetimibe require the patient to upload a recent lipid panel (within 12 months) and a list of current medications before the prescriber approves the prescription.

HealthRX providers licensed in Idaho follow this same protocol. A 10-mg once-daily prescription is generated electronically and transmitted to the patient's preferred Idaho pharmacy or a mail-order pharmacy of the patient's choice. Lipid panels are typically repeated 6 to 12 weeks after initiation to confirm response, consistent with ACC/AHA guideline recommendations [12].

Ezetimibe Dosing, Safety, and Drug Interactions in Idaho Clinical Practice

The only FDA-approved dose is 10 mg once daily, taken with or without food. No renal dose adjustment is needed. Hepatic impairment above Child-Pugh Class B is a contraindication due to increased ezetimibe exposure [1].

The most clinically significant interaction is with bile acid sequestrants. Cholestyramine reduces ezetimibe AUC by approximately 55% when co-administered; dosing should be separated by at least 2 hours before or 4 hours after cholestyramine [1]. Cyclosporine increases ezetimibe exposure by up to 12-fold, requiring dose monitoring in transplant patients [15].

A 2022 meta-analysis in JAMA Cardiology (N=176,000 patients across 14 trials) confirmed that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C from ezetimibe produces approximately the same cardiovascular risk reduction per unit LDL lowering as statins, supporting the "LDL hypothesis" that the vehicle of LDL lowering matters less than the magnitude [16].

Muscle-related adverse events occur at rates indistinguishable from placebo in monotherapy. When combined with statins, myopathy risk is additive with the statin, not specifically attributable to ezetimibe [2]. Liver enzyme elevations above 3x the upper limit of normal occurred in 1.3% of patients in IMPROVE-IT, compared with 1.1% in the placebo arm, a difference that did not reach statistical significance [2].

Monitoring and Follow-Up After Starting Ezetimibe in Idaho

Starting ezetimibe in an Idaho patient requires a baseline lipid panel and liver function tests before initiation, followed by a repeat fasting lipid panel 4 to 12 weeks after the first prescription fill. The ACC/AHA 2018 guideline recommends this monitoring interval regardless of whether ezetimibe is used as monotherapy or as an add-on to statin therapy [12].

Idaho telehealth providers typically use LabCorp or Quest Diagnostics draw sites for follow-up labs. Both maintain multiple locations across Boise, Nampa, Idaho Falls, Pocatello, and Coeur d'Alene. Patients in rural areas of Idaho may use the Idaho Telehealth Network or mail-in finger-stick lipid testing kits that meet CLIA waiver standards.

Patients who do not achieve a 13 to 20% LDL reduction on ezetimibe monotherapy should be assessed for adherence first. A single 30-day supply at $15 has a high adherence rate in studies, with refill rates above 80% at 12 months when cost barriers are removed [17]. If adherence is confirmed and response is inadequate, combination therapy with a statin or the addition of a PCSK9 inhibitor should be considered per ACC/AHA guidelines [12].